anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In critically ill patients, overweight and obesity are associated with acute respiratory distress syndrome and acute kidney injury (AKI). However, the effect of obesity on ischemia-reperfusion injury (IRI)-induced AKI is unknown. We hypothesized that obesity would aggravate renal IRI in mice. We fed mice a standard or high-fat diet for eight weeks. The mice were divided into four groups and submitted to sham surgery or IRI: obese, normal, normal + IRI, obese, and obese + IRI. All studies were performed 48 h after the procedures. Serum glucose, cholesterol, and creatinine clearance did not differ among the groups. Survival and urinary osmolality were lower in the obese + IRI group than in the normal + IRI group, whereas urinary neutrophil gelatinase-associated lipocalin levels, tubular injury scores, and caspase 3 expression were higher. Proliferating cell nuclear antigen expression was highest in the obese + IRI group, as were the levels of oxidative stress (urinary levels of thiobarbituric acid-reactive substances and renal heme oxygenase-1 protein expression), whereas renal Klotho protein expression was lowest in that group. Expression of glutathione peroxidase 4 and peroxiredoxin 6, proteins that induce lipid peroxidation, a hallmark of ferroptosis, was lower in the obese + IRI group. Notably, among the mice not induced to AKI, macrophage infiltration was greater in the obese group. In conclusion, greater oxidative stress and ferroptosis might aggravate IRI in obese individuals, and Klotho could be a therapeutic target in those with AKI.
Direct oral anticoagulant drugs (DOACs) are available in addition to warfarin for the treatment of patients with non-valvular atrial fibrillation (NVAF). Anticoagulants are useful for practical pharmacotherapy in Asian populations, but their responses are different from those in Caucasian populations. Therefore, we aimed to identify the most useful anticoagulant using a nationwide insurance claims database in Japan. We extracted information on patients with NVAF treated with DOACs or warfarin for the first time between September 2015 and February 2018 to conduct a retrospective observational cohort study using the claims database of Japan. We calculated hazard ratios (HR) of effectiveness and safety endpoints among DOACs or warfarin after adjusting for backgrounds by propensity scores (inverse probability weighting). Using negative control outcomes, we considered renal function as an unmeasured confounding factor. After adjusting for their backgrounds, patients treated with DOACs showed higher effectiveness endpoints (stroke or systemic embolism) than those treated with warfarin (HR; 0.72-0.81) and higher safety in terms of safety end points (clinically significant bleeding) (HR; 0.80-0.88). The net clinical benefit, which reflects the actual clinical usefulness, indicates the advantages of DOACs over warfarin (HR; 0.75-0.82). Dabigatran had lower usefulness than edoxaban and rivaroxaban in Japanese patients treated with NVAF, even after considering the unmeasured confounding factor of kidney function. Based on practical clinical data, edoxaban and rivaroxaban were the most useful anticoagulants in Japanese patients with NVAF.
Today, communication devices make our lives easier and provide convenience in the healthcare sector. Some studies have mentioned that a definitive diagnosis can be made with digital photographs and video images in children with normal findings at the time of examination, and further diagnostic tests become unnecessary . Readmission to the hospital after surgery, especially in children, is a situation that increases the level of anxiety. The use of smart device applications to evaluate both the operation site and functional results after many surgical procedures has reduced the number of re-applications and anxiety levels of patients . Through communication, the patient can articulate their needs to the physician, either verbally or visually, and with the assistance of the physician, navigate through this process much more smoothly. In our randomized prospective study, the investigators aimed to assess the role of a mobile phone application facilitating real-time visual and verbal communication, as well as instant information exchange, in reducing emergency room and urology policlinic admissions due to potential complications after circumcision.
The present invention pertains to certain N-alkylcarbonyl-D-amino acid hydroxylalkyl esters (NACHE), including, for example, (R)-2-[((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-propionic acid 3-hydroxy-propyl ester, and compositions comprising such compounds, that target sensory elements on nerve fibers and which are usefully administered to refresh and cool the skin and mucous membranes. This disclosure generally relates to menthol-like cooling compounds, which do not have the smell, taste, or short duration of action of menthol. These compounds are designed for delivery onto the surfaces of the oral cavity, upper respiratory tract and skin. These compositions produce refreshing and cooling sensations and are expected to inhibit the perception of cough stimuli, itch, pain, and discomfort from the body's surfaces. In the oral cavity these compositions produce refreshing cooling without adverse effects on taste. These compounds have special utility for mouth refreshment and for the treatment of respiratory disorders such as cough, asthma, and chronic obstructive pulmonary diseases. In addition, topical use inhibits perception of itch, irritation, pain and discomfort.
OBJECTIVE: Most patients who have an implantable cardioverter-defibrillator (ICD) implant do not receive life-prolonging therapy from it. Little research has been undertaken to determine which patients benefit the least from ICD therapy. As patients age and accumulate comorbidities, the risk of death increases and the benefit of ICDs diminishes. We sought to evaluate the impact of comorbidity, frailty, functional status on death with no prior appropriate ICD therapy.
METHODS: A prospective, multicentre, observational study involving 12 English hospitals was undertaken. Patients were eligible for inclusion for the study if they were scheduled to have a de novo, upgrade to or replacement of a transvenous or subcutaneous ICD or cardiac resynchronisation therapy device and defibrillator (CRT-D). Baseline characteristics were collected. Participants were asked to complete a frailty assessment (Fried score) and a functional status questionnaire (EuroQol 5-Dimension 5-Level (EQ-5D-5L)). The Charlson Comorbidity Index was calculated. Patients were prospectively followed up for 2.5 years. The primary outcome was death with no prior appropriate therapy.
RESULTS: In total, 675 patients were enrolled, mean age 65.7 (IQR 65-75) years. A total of 63 patients (9.5%) died during follow-up, 58 without receiving appropriate ICD therapy. Frailty was present in 86/675 (12.7%) and severe comorbidity in 69/675 (10.2%). Multivariate predictors of death with no appropriate therapy were identified and a risk score comprising frailty, comorbidity, increasing age, estimated glomerular filtration rate and EQ-5D-5L was developed.
CONCLUSION: Comorbidities, frailty and the EQ-5D-5L score are powerful, independent predictors of death with no prior appropriate therapy in ICD/CRT-D recipients.
PURPOSE: A pharmaceutical composition containing Alpinia katsumadai extract, fraction thereof, or tritepenoid compounds is provided to suppress GPAT activity and to prevent and treat metabolic diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating metabolic diseases contains Alpinia katsumadai extract. The extract is isolated using water, alcohol, or mixture thereof. The alcohol includes low carbon number alcohol. The pharmaceutical composition for preventing and treating metabolic diseases contain the fraction prepared using organic solvent. The pharmaceutical composition for preventing and treating metabolic diseases contains triterpenoid compounds of chemical formula 1 or 2 or pharmaceutically acceptable salt thereof as an active ingredient. The compound of chemical formulas 1 and 2 is isolated from Alpinia katsumadai.
The invention belongs to the technical field of Chinese herbal medicines, and discloses a heat-clearing and detoxifying compound composition and a preparation method thereof. Rhizoma Smilacis Glabrae and radix Stemonae are used as principal drugs; cortex pseudolaricis, fructus Cnidii, and cortex Lycii as ministerial drugs; scolopendra, Pheretima, and Eupolyphaga Seu Steleophaga as adjuvant drugs; drynaria rhizome and parasitic loranthus are used as guiding drugs. Mixing with Alumen and Calomelas; sulfur and dried Alumen are combined separately. Not only has the functions of cleaning skin, clearing heat and diminishing inflammation, and relieving itching and pain; also has effects in eliminating dampness, removing toxic materials, removing blood stasis, relieving swelling, killing parasites, and promoting granulation; and has the advantages of quick response, lasting effect, safety and no toxic or side effect. The preparation method comprises respectively mixing formula A and formula B; mixing the formula A and the formula C, and soaking and processing the mixture respectively in white spirit. The medicine amount of the formula A is doubled, and the medicine effect is enhanced; after the medicinal herbs are soaked in the water in groups, the contents of the mineral medicines are diluted, the medicinal properties of the medicinal herbs are more gentle and mild, and the original strong properties of the medicinal herbs are also reduced. After the mixing, soaking and processing, the medicines with different categories and different functions play the due role of the traditional Chinese medicine compound preparation together.
A total of 60 cancer patients who are aged 18 years or above and have persistent peripheral neuropathy for at least 3 months after completion of oxaliplatin-, paclitaxel-, or docetaxel-based chemotherapy will be recruited. After randomization, the experimental group (n = 30) will receive high-frequency rTMS, while the control group (n = 30) will receive sham rTMS. The rTMS will be delivered over M1 (hand representation) of dual hemispheres with 10 trains of 10 Hz pulses for 10 seconds, with a total of 1,000 pulses per hemisphere. The rTMS intensity will be set as 80% resting motor threshold and the interval between each train of pulses will be set as 50 seconds. The rTMS will be delivered as daily session for five consecutive days, followed by two fortnightly maintenance sessions during the follow-up period after the completion of five daily sessions. The rTMS will be delivered by designated physical therapists using "figure-of-8" shaped coil connected to an electromagnetic stimulator in the rehabilitation therapy room of the study hospitals in mainland China.

The research outcomes are feasibility (1. recruitment: i.e. the length of time spent on recruiting participants, the mean number of participants been recruited each month, and the proportion of eligible patients who are finally recruited in the study; 2. eligibility: the proportion of screened patients meeting the inclusion criteria; 3. retention and attrition rates: the proportion of recruited participants who complete the study or who drop out from the study with or without any reason; and 4. appropriateness of clinical outcome measures: the proportion of incomplete questionnaires and neurological tests, as well as the characteristics of the missing data.), acceptability (Chinese version of the Patients' Global Impression of Change \[PGIC\] scale), safety, and trend of improvement in pain, other related symptoms, and quality of life by rTMS in cancer patients with CIPN.
Subverting the host immune response to inhibit inflammation is a key virulence strategy of Yersinia pestis. The inflammatory cascade is tightly controlled via the sequential action of lipid and protein mediators of inflammation. Because delayed inflammation is essential for Y. pestis to cause lethal infection, defining the Y. pestis mechanisms to manipulate the inflammatory cascade is necessary to understand this pathogen's virulence. While previous studies have established that Y. pestis actively inhibits the expression of host proteins that mediate inflammation, there is currently a gap in our understanding of the inflammatory lipid mediator response during plague. Here we used the murine model to define the kinetics of the synthesis of leukotriene B4 (LTB4), a pro-inflammatory lipid chemoattractant and immune cell activator, within the lungs during pneumonic plague. Furthermore, we demonstrated that exogenous administration of LTB4 prior to infection limited bacterial proliferation, suggesting that the absence of LTB4 synthesis during plague contributes to Y. pestis immune evasion. Using primary leukocytes from mice and humans further revealed that Y. pestis actively inhibits the synthesis of LTB4. Finally, using Y. pestis mutants in the Ysc type 3 secretion system (T3SS) and Yersinia outer protein (Yop) effectors, we demonstrate that leukocytes recognize the T3SS to initiate the rapid synthesis of LTB4. However, several Yop effectors secreted through the T3SS effectively inhibit this host response. Together, these data demonstrate that Y. pestis actively inhibits the synthesis of the inflammatory lipid LTB4 contributing to the delay in the inflammatory cascade required for rapid recruitment of leukocytes to sites of infection.
The 8-week weight loss program, ESENCIAL Para Vivir (Essential for Life), is comprised of 6 groups sessions and 2 individual sessions delivered by a bilingiual, bi-cultural Community Health Advisor. All sessions are interactive with activities that build on educative content and most contain an interactive DVD component. We propose an innovative approach that will employ the DVD in tandem with our education sessions delivered by a Community Health Advisor to maximize buy-in from participants as well as provide access to community health leaders (medical professionals - endocrinologists, internists, nutritionists). Participants will be over 19 years of age, self-identifying as Hispanic women without diabetes, not pregnant or have given birth within the previous six months. The participants will be recruited from Jefferson County through community agencies and organization. Participants will be recruited and screened with an initial contact sheet to ensure that they meet our criteria, then they will be consented and complete baseline measurements. At the completion of the program, participants will repeat measures done at baseline, and 6 months post program completion.
The dose received at each injection will be 1.25mg. An injection unique per week will be carried out over 4 consecutive weeks.
1286886 Extraction of bacitracin ROUSSELUCLAF 9 Oct 1970 [10 Oct 1969] 48105/70 Heading C2A In a process for the extraction of bacitracin from a bacitracin-containing liquor, e.g. a fermentation liquor from a bacitracin-producing strain of Bacillus subtilis, a non-ionic adsorbent resin, e.g. a polystyrene or acrylic resin is admixed with the bacitracin-containing liquor, and thereafter the resin (with adsorbed bacitracin) is separated from the liquor, and is extracted with an alcohol, e.g. ethanol or methanol, the bacitracin being subsequently isolated from the resultant alcohol extract, e.g. by distillation under reduced pressure. The resin may be a macroreticular and porous resin and may have an average pore diameter of from 50Š to 250 Š and a specific surface from 50 m.<SP>2</SP>/g. to 1000 m.<SP>2</SP>/g. The bacitracin-containing liquor may be repeatedly admixed with fresh resin before discard. The bacitracin-containing liquor may be left in contact with the non-ionic resin after each admixture for a period of one to 15 hours. The resin may be mixed with the liquor in quantities ranging from 100-350 parts by volume to 1000 parts by volume of liquor. The alcohol used to extract the bacitracin from the resin may be from twice to five times the volume of the resin. Pharmaceutical compositions having antibiotic properties may be prepared using bacitracin prepared by the process of the invention.
The present invention relates to the field of liquid solubilising systems. More specifically, the present invention relates to a macroemulsion comprising a hydrophobic active substance, which enhances the transfer of said hydrophobic active substance to a subject or object. A method for producing the macroemulsion, and the use of said macroemulsion to provide a sensory effect or other benefits, are likewise provided. The present invention also pertains to the use of the macroemulsion for preparing consumer products. Consumer products comprising or consisting of said macroemulsion, such as foods, cosmetics, personal care products, in particular skin cleaning products, shampoos, rinse-off conditioners, deodorants, antiperspirants, body lotions, homecare products, in particular liquid detergents, all-purpose cleaners, laundry and cleaning agents, fabric softeners, laundry scent, laundry scent boosters, pharmaceuticals and pet foods, in particular laundry and cleaning agents, also form part of the present invention. The present invention especially pertains to laundry scent or laundry scent booster products which impart laundry an intensive fragrance effect.
A 33-5/7, 1570 g dichorionic diamniotic twin presented with cryptorchidism, failed hearing examination (both ears), poor feeding, profound hypoglycemia, coagulopathy, conjugated hyper-bilirubinemia, hydronephrosis, and hypotension. Microarray sent with results of whole genome SNP microgray analysis detected an interstitial duplication of the chromosomal segment 4q35 1q35.2. On this basis, telemedicine screening was performed to evaluate for ocular abnormalities in association with abnormal gene testing. Unilateral advanced retinopathy was noted affecting the right eye, with mature vascularization in the left eye. This infant was managed in concordance with retinopathy of prematurity guidelines, despite not making screening criteria. Off-label intravitreal bevacizumab injection (0.625 mg in 0.025 mL) resulted in full vascular maturation assessed by fluorescein angiography 6 months later. This represents the first description and management of retinopathy in 4q duplication syndrome. [Ophthalmic Surg Lasers Imaging Retina 2024;55:228-230.].
With the increasing availability of predictive genetic testing for adult-onset neurodegenerative conditions, it is imperative that we better understand the impact of learning one's risk status. Frontotemporal degeneration (FTD) is the second most prevalent cause of early-onset dementia. About one-third of patients have an identifiable genetic etiology, and some genetic variants that cause FTD can also cause amyotrophic lateral sclerosis (ALS). To understand individuals' risk perception and broader experience of living at risk, we completed semi-structured telephone interviews with 14 asymptomatic adults who tested positive for a variant known to cause risk for FTD and/or ALS. We conducted a thematic analysis, and within the core topic of identity, we derived three themes: conceptualization of FTD and ALS as a threat to identity, enduring uncertainty and dread, and varying centrality of risk status to identity. FTD and ALS risk raised fundamental issues for participants related to the essence of personhood, challenged them to confront Cartesian dualism (the philosophy of mind-body separation), and exposed how time, relationships, and social roles have affected their understanding of the nature of the self. Our findings provide important insight into how being at genetic risk shapes an individual's identity. We conclude that genetic counseling interventions that allow for identity exploration, anticipatory guidance, and uncertainty management should be utilized when supporting persons at risk.
In this stepped wedge design, cohorts of community-based clinicians receive a training in how to conduct an evidence-based cognitive behavioral intervention in suicide prevention for justice-involved youth. There are 15 clinicians in each training cohort.
The present invention relates to the application of loxoprofen sodium for preparing gynecological disease medicines. The existing loxoprofen sodium is only used for relieving pain and inflammation for chronic rheumatic arthritis, arthritis deformans, lumbago, periarthritis humeroscapularis, neck omitis, etc., but can not be used for treating other diseases. The loxoprofen sodium is applied to treat pain caused by the gynecological disease through the present invention, especially dysmenorrhea, and the effect is obvious. The loxoprofen sodium is applied to dysmenorrhea patients whose pain can not be reduced by any other medicines, and the symptom is obviously relieved and disappears. The method for preparing tablets or granules by the loxoprofen sodium is simple, and the tablet preparing performance is good. The present invention widens the novel application field of the loxoprofen sodium, which brings benefits for gynecological disease patients.
The invention discloses a traditional Chinese medicine compound preparation for treating chicken ascites syndrome. The preparation comprises the following components in parts by weight: 3-6 parts of radix bupleuri, 2-5 parts of indigo naturalis, 3 parts of grifola and 1-2 parts of fructus kochiae. The preparation is prepared by adding cane sugar after decoction. The traditional Chinese medicine compound preparation for treating chicken ascites syndrome with reasonable components of traditional Chinese medicines has the function of treating chicken ascites syndrome. The traditional Chinese medicine compound preparation for treating chicken ascites syndrome and a preparation method are provided for the breeding industry. The traditional Chinese medicine compound preparation has the characteristics of quick effect, exact curative effect, no medicine residue and no toxic and side effects. The traditional Chinese medicine oral liquid is convenient to transport, quick to use and simple in preparation method, and is suitable for demands of large-scale industrial production.
The invention provides a shRNA transgenic recombinant plasmid for inhibiting swine influenza viruses. The plasmid contains four shRNA expression genes for simultaneously coding four specific shRNAs capable of respectively targeting influenza virus Pa, PB1, PB2 and NP gene conserved regions. The plasmid is suitable for a plurality of transgenic technologies. After the plasmid is transferred into a MDCK cell cultivated in vitro by a lentivirus carrier, a challenge assay proves that the screened transgenic cell line has a function of resisting infection caused by different subtypes of influenza viruses. The plasmid is injected into a pigling with 4 week old by intravenous injection and intramuscular injection and then the pigling is infected by H3N2 subtype of pig influenza viruses, and the test result shows that an influenza virus replication inhibition function of the blood injection group is better. RNAi is used for pig influenza virus research and pig influenza prevention and treatment so that necessary experiment data is accumulated and thus a base is established for researching influenza resistance of a transgenic pig.